Tyrosine mutation in AAV9 capsid improves gene transfer to the mouse lung

Cellular Physiology and Biochemistry

Volumn 39, Issue 2, 2016, Pages 544-553

  Martini, Sabrina V ^a   Silva, Adriana L ^a   Ferreira, Debora ^a   Rabelo, Rafael ^a   Ornellas, Felipe M ^a   Gomes, Karina ^a   Rocco, Patricia R M ^a   Petrs Silva, Hilda ^a   Morales, Marcelo M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adeno associated virus serotype 9; Gene therapy; Lung mechanics; Tyrosine mutant

Indexed keywords

ADENOVIRUS VECTOR; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEASOME; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE; CAPSID PROTEIN; CYTOKINE; GREEN FLUORESCENT PROTEIN; SIGNAL PEPTIDE;

ADENO ASSOCIATED VIRUS 9; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME DEGRADATION; GENE EXPRESSION; LUNG; LUNG INJURY; LUNG MECHANICS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; POINT MUTATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; TRANSGENE; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE; WILD TYPE; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROCEDURES; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CAPSID PROTEINS; CYTOKINES; DEPENDOVIRUS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MALE; MICE, INBRED C57BL; POINT MUTATION; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TRANSGENES; TYROSINE;

EID: 84978151018     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000445646     Document Type: Article

References (42)

1. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE: Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18:726-732.
2. Halbert CL, Madtes DK, Vaughan AE, Wang Z, Storb R, Tapscott SJ, Miller AD: Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010;18:1165-1172.
3. Devaney J, Curley GF, Hayes M, Masterson C, Ansari B, O'Brien T, O'Toole D, Laffey JG: Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Crit Care 2013;17:R82.
4. Gubrij IB, Martin SR, Pangle AK, Kurten R, Johnson LG: Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther 2014;25:498-505.
5. He SS, Shi HS, Yin T, Li YX, Luo ST, Wu QJ, Lu L, Wei YQ, Yang L: AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol Rep 2012;27:1142-1148.
6. Qi YF, Li QH, Shenoy V, Zingler M, Jun JY, Verma A, Katovich MJ, Raizada MK: Comparison of the transduction efficiency of tyrosine-mutant adeno-associated virus serotype vectors in kidney. Clin Exp Pharmacol Physiol 2013;40:53-55.
7. Schultz BR, Chamberlain JS: Recombinant adeno-associated virus transduction and integration. Mol Ther 2008;16:1189-1199.
8. Grimm D, Kay M: From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003;3:281-304.
9. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM: Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009;17:294-301.
10. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB: Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003;14:1079-1088.
11. Halbert CL, Miller AD, Namara SMC, Emerson J, Gibson RL, Ramsey B, Aitken ML: Prevalence of neutralizing antibodies against cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17:440-447.
12. Lassance RM, Caroline PP, Martini SV, Castiglione RC, Gutierrez TM, Abreu SC, Antunes MA, Xisto DG, Cebotaru L, Petrs-Silva H, Zin WA, Guggino WB, Linden R, Rocco PR, Morales MM: Does the use of recombinant AAV2 in pulmonary gene therapy damage lung function? Respir Physiol Neurobiol 2008;160:91-98.
13. Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, Samuel R, Rajalingam S, Ramya V, Nair SC, Srinivasan N, Srivastava A, Jayandharan GR: Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 2013;24:104-116.
14. Kotterman MA, Schaffer DV: Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 2015;15:445-451.
15. Qiao C, Yuan Z, Li J, Tang R, Li J, Xiao X: Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum Gene Ther Methods 2012;23:29-37.
16. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A: Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008;105:7827-7832.
17. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, Hauswirth WW: High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:1463-1471.
18. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW: Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013;121:2224-2233.
19. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM: Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-6388.
20. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM, Sweeney HL: Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008;19:1359-1368.
21. Foust KD, Nurre E, Montgomery CL, Hernandez A, Curtis M, Kaspar BK: Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65.
22. Wang RL, McLaughlin T, Cossette T, Tang Q, Foust K, Campbell-Thompson M, Martino A, Cruz P, Loiler S, Mueller C, Flotte TR: Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol Ther 2009;17:81-87.
23. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA: The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006;80:9831-9836.
24. Martin EL, Sheikh TA, Leco KJ, Lewis JF, Veldhuizen RA: Contribution of alveolar macrophages to the response of the TIMP-3 null lung during a septic insult. Am J Physiol Lung Cell Mol Physiol 2007;293:L779-789.
25. Gill J, ed: Models of Lung Disease -Microscopy and Structural Methods. New York: Marcel Dekker; 1990, pp 199-247.
26. Martini SV, da Silva AL, Ferreira D, Gomes K, Ornellas FM, Lopes-Pacheco M, Zin E, Petrs-Silva H, Rocco PR, Morales MM: Single tyrosine mutation in AAV8 vector capsid enhances gene lung delivery and does not alter lung morphofunction in mice. Cell Physiol Biochem; 2014; 34: 681-690.
27. Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H, Chiodo V, Neeley AW, Govindasamy L, Bennett A, Agbandje-McKenna M, Zhong L, Li B, Jayandharan GR, Srivastava A, Lewin AS, Hauswirth WW: Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19:293-301.
28. Sen D: Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering. J Biomed Sci 2014;21:103.
29. Hakim CH, Yue Y, Shin J-H, Williams RR, Zhang K, Smith BF, Duan D: Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs. Mol Ther Methods Clin Dev 2014;1:14002.
30. Song L, Li X, Jayandharan GR, Wang Y, Aslanidi GV, Ling C, Zhong L, Gao G, Yoder MC, Ling C, Tan M, Srivastava A: High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PLoS One 2013;8:e58757.
31. Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, Zhong L: High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther 2010;21:1527-1543.
32. Morales MM, Capella MA, Lopes AG: Structure and function of the cystic fibrosis transmembrane conductance regulator. Braz J Med Biol Res 1999;32:1021-1028.
33. Elborn JS: Cystic fibrosis. Lancet DOI: 10.1016/S0140-6736(16)00576-6.
34. De Boeck K, Amaral MD: Progress in therapies for cystic fibrosis. Lancet Respir Med DOI: 10.1016/S2213-2600(16)00023-0.
35. Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD: Five percent of normal cystic fibrosis transmembrane conductance regulator RNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002; 27: 619-627.
36. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P: The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (delta F508). N Engl J Med 1990;323:1517-1522.
37. Vandendriessche T, Thorrez L, Acosta-Sanchez A, Petrus I, Wang L, Ma L, Iwasaki Y, Gillijns V, Wilson JM, Collen D, Chuah MK: Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007;5:16-24.
38. Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, Ng P, Herzog RW, Lee B: Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther 2013;21:796-805.
39. Zhu J, Huang X, Yang Y: The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009;119:2388-2398.
40. Sudres M, Ciré S, Vasseur V, Brault L, Da Rocha S, Boisgérault F, Le Bec C, Gross DA, Blouin V, Ryffel B, Galy A: MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther 2012;20:1571-1581.
41. Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci USA 2011;108:3743-3748.
42. Da Silva AL, Martini SV, Abreu SC, Samary CDS, Diaz BL, Fernezlian S, de Sá VK, Capelozzi VL, Boylan NJ, Goya RG, Suk JS, Rocco PR, Hanes J, Morales MM: DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J Control Release 2014;180:125-133.